A TRIAL TO STUDY THE EFFECTS OF ATORVASTATIN IN PATIENTS WITH CHRONIC SCHIZOPHRENIA
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2019/01/017304
- Lead Sponsor
- CENTRAL INSTITUTE OF PSYCHIATRY
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
a) Patients admitted in the Institute and satisfying the ICD 10-DCR[1993] criteria for schizophrenia[ with illness duration more than or equal to 2 years] b) Age group of 18-50 years of both sexes c) Drug naive patients or drug free for minimum 2 weeks on oral antipsychotics & 4 weeks for depot preparation d) Those who give informed consent for participating in the study.
a) Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine. b) Significant medical or neurological illness including severe cardiovascular, hepatic, renal,[serum creatinine > 1.5 mg/dl], anaemia [Haemoglobin < 11 mg/dl], history of severe head injury or myopathy or untreated thyroid disease. c) Pregnancy
8 | P a g e
d) BMI >30 kg/m2 e) Not willing to give written informed consent f) Current treatment with Insulin, medications known to affect glucose tolerance anti-inflammatory drugs including NSAIDS, thiazide diuretics, agents that induce weight loss]. g) Current treatment with drugs that induce or inhibit metabolism of statins [Azole antifungals, Macrolide antibiotics, Carbamazepine, anti-retroviral protease inhibitors] h) Known hypersensitivity to Tab. Atorvastatin or any of its components i) Any current systemic infection/ inflammation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method